Cardio Diagnostics Holdings Inc. has announced an expansion of its precision cardiovascular care solutions across the U.S. mainland and Puerto Rico. The company is partnering with a new cohort of healthcare practices, offering its innovative clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™, to a diverse range of care models including concierge, direct primary care, and integrative medicine. This expansion aims to provide proactive, personalized cardiovascular care to more patients, supporting the shift towards preventive cardiology. The partnerships extend to independent practices in states like Indiana and Ohio, as well as a nationally connected network of direct primary care providers. Cardio Diagnostics' solutions are designed to provide earlier, more personalized insights into heart health, aligning with their mission to prioritize individualized patient care and early detection of cardiovascular disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.